読み込み中
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.
前日終値
$3.40
−$0.06 · -1.73%
日中の時刻はETです。市場データは遅延する場合があります。
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.
日中レンジ
現在 $3.40
52週レンジ
現在 $3.40
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
21
割高
センチメント
53
まちまち
リスク
59
やや高いリスク
モメンタム
58
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.
日中レンジ
現在 $3.40
52週レンジ
現在 $3.40
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1189.74万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM714.63万0.01%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF412.38万0.00%954億 USD0.05%$235+0.80%
State Street SPDR S&P Pharmaceuticals ETFXPH353.58万0.77%4.62億 USD0.35%$64.65+1.60%
iShares Russell 2000 Growth ETFIWO209.25万0.02%139.17億 USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO199.7万0.01%180億 USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA160.78万0.01%218.24億 USD0.03%$32.79+0.40%
Dimensional - US Small Cap ETFDFAS145.73万0.00%338.69億 USD0.31%$78.35+0.32%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHADimensional - US Small Cap ETFDFASAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
